10.07
-0.15 (-1.47%)
| Penutupan Terdahulu | 10.22 |
| Buka | 10.21 |
| Jumlah Dagangan | 145,053 |
| Purata Dagangan (3B) | 288,937 |
| Modal Pasaran | 199,303,776 |
| Harga / Pendapatan (P/E Ke hadapan) | 48.78 |
| Harga / Jualan (P/S) | 9.86 |
| Harga / Buku (P/B) | 0.700 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | 1.96% |
| Margin Operasi (TTM) | 71.97% |
| EPS Cair (TTM) | -0.170 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 254,413.31% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.53% |
| Nisbah Semasa (MRQ) | 19.29 |
| Aliran Tunai Operasi (OCF TTM) | 44.86 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 30.29 M |
| Pulangan Atas Aset (ROA TTM) | -1.01% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Keros Therapeutics, Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.17 |
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.31% |
| % Dimiliki oleh Institusi | 109.35% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |